Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly (NYSE:LLY) on Thursday reported its Q4 2024 results, exceeding Wall Street forecasts and indicating a more than twofold rise in revenue from its weight loss and obesity drugs Mounjaro and ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

New research found that over half of people with type 2 diabetes in the Americas may be deficient in essential nutrients, ...

Using patient kidney biopsies, the team developed a new method to measure glycocalyx thickness, confirming that the layer is ...

As the number of people with diabetes and pre-diabetes surges in the UK, we take a look at how to reverse the condition.

Almost 2% of the U.S. population received prescriptions for the weight-loss and diabetes drugs semaglutide and tirzepatide in ...

The company's shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

At CommunityHealth, which serves a large immigration population, prescriptions have been left on shelves since President Donald Trump took office.